Attractive Targeted Sugar Baits for malaria control in western Kenya (ATSB-Kenya) – Effect of ATSBs on epidemiologic and entomologic indicators: a Phase III, open-label, cluster-randomised, controlled trial

Caroline Ogwang[1,2*], Aaron M Samuels[3,4], Daniel P McDermott[5], Alice Kamau[1,2], Maia Lesosky [2,#a], Kizito Obiet[1], Julia M Janssen[3], Wycliffe Odongo[3], John E Gimnig[3], Julie R Gutman[3], Jonathan S Schultz[3,4], Oliver Towett[1], Brian Seda[1], Mercy Chepkirui[1], Margaret Muchoki[1], Seline Omondi[1], Jackline Kosgei[1], Brian Polo[1], Frank Aduwo[1], Kephas Otieno[1], Martin J Donnelly[5], Simon Kariuki[1], Eric Ochomo[1,5], Feiko ter Kuile[1,2¶] Sarah G Staedke[1,2,5¶]

[1] KEMRI Centre for Global Health Research, Kisumu, Kenya

[2] Department of Clinical Sciences, Liverpool School of Tropical Medicine, UK

[3] Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

[4] Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Kisumu, Kenya

[5] Department of Vector Biology, Liverpool School of Tropical Medicine, UK

[#a] Current Address: National Heart and Lung Institute, Imperial College London, UK

* Corresponding author; E-mail: caroline.ogwang@lstmed.ac.uk (CO)

¶These authors contributed equally to this work.

Abstract

Attractive targeted sugar baits (ATSBs) are a novel malaria control tool designed to target mosquitoes outdoors. We conducted a cluster-randomised trial to evaluate the impact of ATSBs on malaria indicators in Kenya. Seventy clusters (≥100 households/cluster) in Siaya county were randomly assigned (1:1) to intervention or control. Pyrethroid-only long-lasting insecticidal nets were distributed to all clusters, aiming for universal coverage. Two ATSBs containing dinotefuran were hung outside household structures in intervention clusters. ATSBs were monitored every two months and replaced every six months over two years. Three consecutive cohorts of randomly selected children (1-<15 years) were enrolled, aiming to accrue 1,260 person-years over two years of follow-up. Incidence of clinical malaria (fever with a positive malaria test) was the primary outcome. A multilevel Poisson regression model was applied, with clusters as a random intercept and study arm as a fixed effect. Secondary outcomes were malaria prevalence in community residents (≥1 month), and parity of mosquitos captured through human landing catches. In March 2022, ATSBs were delivered to 33,180 of 33,419 (99.3%) household structures in intervention clusters. Overall, 268,268 ATSBs were deployed over two years. Of 2,962 cohort children enrolled (intervention=1,497; control=1,465), 2,869 (96.9%) were included in the primary analysis (intervention=1,461; control=1,408), contributing 1,445 person-years of follow-up. Malaria incidence was 1.32 episodes per person-years in the intervention arm versus 1.20 in the control (unadjusted incidence rate ratio 1.11; 95% CI: 0.75-1.65; p=0.598). Of 7,488 community residents surveyed (intervention=3,760; control=3,728), 1,474 (39.2%) intervention and 1,461 (39.2%) control participants tested positive for malaria (unadjusted odds ratio [OR] 0.98; 95% CI: 0.60-1.59; p=0.93). Of 6,457 female anopheles mosquitoes collected (intervention=4,058; control=2,399), 3,579 (88.2%) intervention and 1,973 (82.2%) control mosquitoes were parous (OR 1.34; 95% CI: 0.91-1.99; p=0.14). In Kenya, we found no evidence that ATSBs reduced clinical malaria incidence, malaria prevalence, or vector parity.

Trial registration

Clinicaltrials.gov (NCT05219565), 22 January 2022; https://clinicaltrials.gov/study/NCT05219565

Keywords

malaria, attractive targeted sugar bait (ATSB), vector control, cluster-randomised trial, Kenya

Introduction

Between 2000 to 2015, the prevalence and incidence of *Plasmodium falciparum* in Africa fell by 50% and 40%, respectively, primarily due to the scale-up of long-lasting insecticidal nets (LLINs), indoor residual spraying (IRS) and treatment with artemisinin-based combination therapies (ACTs) [1]. Since 2015, however, progress on malaria control has plateaued [2]. Malaria control efforts were hindered by the COVID-19 pandemic, but widespread resistance to pyrethroid insecticides, climate change, fluctuations in vector species, changes in mosquito behaviours, and resistance to artemisinin and partner drugs are other threats [2-6]. In Kenya, malaria burden remains high in the western, lake-endemic region, despite distribution of LLINs and targeted IRS [7].

LLINs are the most widely used vector control tool, supplemented by IRS [2]. Both tools target mosquito vectors that feed and rest indoors. However, vector behaviours are shifting, with increased biting outdoors and later in the morning hours, when individuals are less likely to be protected by LLINs [5, 8]. Novel tools, such as attractive targeted sugar baits (ATSBs) that target mosquitoes outdoors are needed to complement other control interventions deployed indoors. ATSBs are A4-sized panels containing fruit syrup laced with an insecticide, which exploits the sugar-feeding behaviour of mosquitoes [9]. ATSBs attract mosquitoes, luring them to feed and ingest the insecticide, which kills the mosquitoes.

In 2017, an initial entomological field trial of ATSBs was conducted in Mali, which found ATSBs were associated with significant reductions in vector density, sporozoite rate, and entomologic inoculation rate (EIR) associated with ATSBs [10]. Subsequent modelling studies suggested that ATSBs could reduce malaria incidence and parasite prevalence by over 30% annually [11]. Given these promising results, results from Zambia indicating that *Anopheles funestus* and *An. gambiae* fed readily from the ATSB stations [12], and the predicted impact of ATSBs on malaria transmission [11, 13], large-scale, Phase III cluster-randomised, controlled trials were launched in 2021 to further evaluate the

epidemiological and entomological impact of ATSBs in Kenya, Mali and Zambia [14]. Here, we present the results of the Kenyan trial.

Methods

The protocol and statistical analysis plan for the multi-country ATSB trial have been published previously [14, 15]. A description of cohort recruitment (Fig1), and the characteristics of children and households at enrolment, have also been published [16].

Study setting

The trial was conducted in Alego-Usonga and Rarieda sub-counties in Siaya County, western Kenya (Fig2), in the region of the Health and Demographic Surveillance System (HDSS) established by the Kenya Medical Research Institute and the US Centers of Disease Control and Prevention, which has been described in detail [17, 18]. Briefly, malaria transmission is perennial in this area with prevalence peaking between May-June and November-December, following the long and short rains. Malaria prevalence by microscopy in the study area was 36.8% in 2013, and was highest in children aged 5-14 years (57.9%) [19]. The primary malaria vectors are *An. funestus* and *An. arabiensis* [5, 20]. Artemether-lumefantrine (AL) has been used as the first-line therapy for case management since 2006, LLIN mass campaigns are conducted every 3-5 years (2014, 2017, 2021), and IRS is not implemented in this area [21].

Assignment of interventions

Following a census conducted from December 2020 to March 2021, we established 80 clusters by purposely grouping 1-3 adjacent villages to create a cluster of sufficient population size. To minimise contamination, clusters were divided into core and buffer areas, with core areas 300-600 meters from the perimeter, and 600-1,200 meters between cores of contiguous clusters. We aimed for a

core population of 100-400 households. Prior to randomisation, malaria incidence, prevalence, and contextual data were collected in the 80 clusters. Subsequently, 10 clusters with the fewest children aged 1-<15 years were removed, to limit resampling of individuals. Thus, 70 of the original 80 clusters were included in the trial.

Clusters were assigned to study arms using restricted randomisation to minimise imbalances, considering key baseline characteristics (malaria incidence, bednet use, RTS,S/AS01 vaccination implemented within the cluster, housing density, study clinic location, altitude, and entomological indicators), as described previously [14, 15]. A list of 100,000 possible allocation sequences was generated by a study team member not involved in trial implementation and checked against balance criteria. Any sequences that failed to balance these criteria were dropped. The remaining sequences were assessed for validity, and one was chosen randomly. Assignment to intervention or control was determined by a coin toss. The 70 clusters (32 in Alego Usonga and 38 in Rarieda) were randomised in a 1:1 ratio, 35 to the intervention arm and 35 to control. Allocation of study arms was not blinded to the investigators, field team or participants. However, laboratory technicians were blinded.

Intervention delivery

ATSB® Sarabi Bait Station (version 1.2, Westham Co., Hod-Hasharon, Israel) containing dinotefuran, a neonicotinoid insecticide, were deployed to consenting households in the 35 intervention clusters, in both core and buffer areas, beginning in March 2022 (see timeline in Fig3). Two ATSB stations were hung approximately 1.8 meters above the ground on the exterior walls of all eligible household structures (those with a complete roof, walls ≥1.8 m high, and at least three complete exterior walls). The study team visited households to monitor ATSBs every two months. ATSBs that were missing or damaged were replaced, and all ATSB stations were replaced every six months. Four rounds of ATSBs were deployed over two years. All ATSBs were removed from the field in April 2024;

110 used ATSBs were incinerated. Pyrethroid-only LLINs were distributed in Siaya county by the Kenyan
111 Ministry of Health in June 2021, aiming to achieve universal coverage (one LLIN for every two
112 household residents). During the trial, the study team delivered supplemental pyrethroid-only LLINs
113 to all clusters in October 2022 to households with inadequate LLIN coverage (less than one LLIN per
114 two residents).
115
116 **Cohort study**
117 Three consecutive cohorts of children aged 1-<15 years were enrolled in March-April 2022,
118 September-October 2022, and March-April 2023. The first two cohorts were followed for up to 6.5
119 months, while the third cohort was followed for up to 12.5 months. In total, the cohorts were
120 followed from March 2022 to April 2024.
121
122 A list of randomly selected children aged 1-<15 years was generated for recruitment from the
123 baseline census list for each cluster. A new list was generated for each cohort. Children on the
124 recruitment list were invited for a screening appointment at one of nine dedicated study clinics
125 staffed by study clinicians and community interviewers. Children were enrolled in the cohort study if
126 they met the following selection criteria: (1) age 1 to < 15 years; (2) resident of the household (over
127 the previous four months, and intending to stay for an additional 6-12 months); (3) provision of
128 written informed consent by their parent or guardian; (4) provision of assent by children aged 13-14
129 years; (5) no evidence of pregnancy; (6) not taking cotrimoxazole prophylaxis; (7) no known sickle
130 cell disease; (8) no contraindication to AL; and (9) not currently enrolled in another interventional
131 study or enrolled in the previous ATSB cohort.
132
133 At enrolment, information was collected on demographics, clinical history, and self-reported LLIN
134 use the previous night. Children were asked about history of fever within the past 48 hours, and
135 axillary temperature was measured. A finger-prick blood sample was collected for rapid diagnostic

136 test (RDT) for malaria (First Response® Malaria Ag pLDH/HRP2 Combo Card kit) and storage on filter
137 paper at -80°C for future molecular studies. All participants were treated with AL, regardless of the
138 RDT result. Two weeks after enrolment, participants were asked to return to the clinic to assess
139 parasite clearance. Participants testing positive at the clearance visit were treated with either AL or
140 dihydroartemisinin-piperaquine (DP), according to Ministry of Health guidelines. A household survey
141 was conducted soon after enrolment to collect information on household characteristics, house
142 construction, indicators of socioeconomic status, and LLIN ownership.
143
144 Cohort participants were encouraged to seek care at study clinics and were scheduled for routine
145 clinic visits every 4 weeks. At each monthly visit, information was collected on any recent illness,
146 care-seeking, LLIN use, and travel history. A finger-prick capillary blood sample was collected for
147 storage on filter paper. If the cohort participant missed a scheduled visit, their parent or guardian
148 was called. If we failed to reach them after three attempts, a field worker was sent to their house. If
149 a participant sought care outside of the study, information on symptoms, malaria testing, and
150 antimalarial treatment were recorded. If a child was febrile (axillary temperature ≥37.5˚C or history
151 of fever in the previous 48 hours) at any clinic visit, a RDT was performed. If the child had been
152 treated for malaria within the past 5 weeks, a blood smear was prepared for microscopy, instead of
153 an RDT. If the RDT or blood smear was positive, the child was treated according to the Kenya
154 Ministry of Health guidelines with AL or DP. Children with severe malaria were referred to the
155 nearest hospital for treatment with parenteral artesunate. Cohort participants were excluded after
156 enrolment if they withdrew consent, moved out of the study area, or met any of the exclusion
157 criteria for cohort participation.
158
159 **Continuous malaria indicator surveys (cMIS)**
160 A cMIS survey measured malaria prevalence cross-sectionally in community residents throughout
161 the year from April 2022 to February 2024. Households from each cluster were randomly selected

162 from a census list and were visited once. Written informed consent and assent (for children aged 13-
163 17 years) were sought for all household residents (aged ≥1 month) who were present on the day of
164 the survey. Information on demographics, housing characteristics, and LLIN ownership and use was
165 obtained from the head of household, or their designee. A finger-prick blood sample was collected
166 from each consenting participant for an RDT. Participants who tested positive were treated with AL.
167

168 **Entomology surveys**

169 Mosquito collections using human landing catches (HLC) and CDC ultraviolet light traps (UVLT) were
170 conducted monthly from April 2022 to March 2024 in 16 randomly selected clusters using a stratified
171 approach to ensure study arm assignments were balanced across the area. Trained community
172 members consented to participate as mosquito collectors. Ten households enrolled in the cohort
173 study were randomly chosen per cluster to participate in the HLCs. Initially, HLC collections were
174 conducted indoors and outdoors from 6:00 PM to 6:00 AM. In October 2022, the sampling period
175 was extended to 11:00 AM to capture late morning biting. UVLT collections were paired with the
176 HLCs and conducted in the same 16 clusters, but in ten different households located within 50
177 meters of each HLC household. The timing of UVLT collections mirrored the HLCs. Seven cross-
178 sectional UVLT collections were also done in the 70 clusters, in February 2022 (baseline), May and
179 November 2022, May, July and November 2023, and February 2024 (Fig3). At each point, ten
180 households were randomly sampled in the remaining 54 clusters, resulting in comprehensive data
181 from all 70 clusters.

182

183 **Laboratory procedures**

184 For microscopy, thick and thin blood smears were prepared on the same slide by study clinicians and
185 were transported to the laboratory in Siaya County. Details on slide preparation and microscopy
186 procedures are included in the supplemental file. All slides were read by a second microscopist, and

187 a third independent reviewer settled any discrepant readings. Mosquitoes collected using HLCs and
188 UVLTs were transported to the laboratory for morphological identification. All undamaged, unfed
189 female *Anopheles* spp. mosquitoes captured alive during HLCs were dissected to assess parity by the
190 ovary tracheation method [22].
191

192 **Sample size calculations**

193 Full details of the sample size calculations are provided in the trial master protocol and statistical
194 analysis plan [14, 15]. A sample size of 1,260 person-years (630 person-years per arm) was required
195 to detect a ≥30% reduction in the incidence of clinical malaria among children aged 1-<15 years
196 (from 845 per 1,000 person-years in the control arm to 592 in the intervention arm over two years),
197 assuming a coefficient of variation of 0.4, two-sided alpha of 0.049, 80% power, and an anticipated
198 20% loss of person-time due to loss to follow up or consent withdrawal. For cMIS, a sample size of
199 4,200 participants annually (60 per cluster) was required to detect a 30% reduction in RDT-
200 confirmed malaria prevalence, from 29.0% to 20.3%, assuming an intra-cluster correlation
201 coefficient (ICC) of 0.05, 80% power, a two-sided alpha of 0.05, and a 20% non-response rate,
202 allowing for analysis within each 6-month sampling period. For vector parity, simulations (n=1,000)
203 accounting for variation between clusters, household, months and monthly catch were conducted
204 [23], assuming a two-sided alpha of 0.05, power of 80%, ICC of 0.04, expected female *Anopheles* per
205 trap night of 2.5, and 16 clusters (8 per arm). To detect a 9%-point reduction, from 50% parity in the
206 control arm, we estimated that ten entomological collections per cluster per month were required.
207

208 **Outcome measures**

209 Incidence of malaria (clinical malaria cases per person-year) in children aged 1-<15 years was the
210 primary outcome, defined as fever (axillary temperature of ≥37.5°C or history of fever within the
211 past 48 hours) plus a positive malaria test (RDT or microscopy). Malaria cases diagnosed within 14
212 days of AL treatment, or 28 days of DP treatment, were not counted as incident cases. To account

213 for the post-treatment prophylactic effect of AL and DP, the at-risk person-time was adjusted by
214 subtracting 14 days for each AL treatment, and 28 days for each DP treatment. Temporary absences
215 from the study area that did not interfere with monthly clinic visits were not considered to reduce
216 individual exposure time. However, absences >35 days were excluded from exposure time.
217 Secondary outcomes included (i) malaria prevalence: proportion of participants aged ≥1 month
218 testing positive by RDT; (ii) parity: proportion of dissected mosquitoes that were parous; (iii) vector
219 density (the number of female *Anopheles* collected per household). All entomological outcomes
220 were calculated for all *Anopheles* spp. collected and disaggregated by species complexes based on
221 morphological identification.
222

223 **Analytical approach**

224 All analyses were done using the intention-to-treat population. For the primary outcome, a multi-
225 level variance components model within a generalised linear framework with a Poisson likelihood
226 and a log link function was used. A random intercept was included for cluster, and study arm was
227 included as a fixed effect. We examined the distributional assumption that the mean and variance of
228 the outcome were similar after accounting for cluster effects. Adjusted analyses including pre-
229 specified covariates (sub-county, age, gender, housing type, baseline cluster-level malaria incidence
230 and adequate bednet coverage, defined as one net per two residents) were conducted [15]. Other
231 factors considered in the restricted randomisation were not included in the adjusted (or unadjusted)
232 analyses. Household structures were classified as 'improved' (finished walls and roofs, and closed
233 eaves) or 'traditional' (all other construction). Subgroup analyses by factors specified a priori (age,
234 gender, baseline parasite prevalence, housing type) were also conducted by including the subgroup
235 variable and an interaction term with study arm in an adjusted analysis. If the *p*-value of the
236 interaction terms was <0.05, separate effect estimates and confidence intervals for each sub-group
237 were presented.
238

Malaria prevalence was analysed using a multi-level variance components model within a generalised linear framework, with a Bernoulli likelihood and a logit link function. A random intercept was included for each study cluster, and the study arm was treated as a fixed effect. Adjusted analyses included pre-specified covariates (region, age, gender, bednet use) [15]. Vector parity and density were analysed using individual-level data through generalised linear mixed models. Both unadjusted and adjusted analyses were conducted, with a random effect for clusters included in the models. For the unadjusted analysis of parity, a Bernoulli likelihood was used with a logit link function and a fixed effect for the study arm. The adjusted analysis included fixed effects for collection location (indoors vs. outdoors), time since intervention, and calendar month for seasonality. For density, a negative binomial distribution was used to account for overdispersion. The unadjusted analysis included a fixed effect for the study arm, while the adjusted model considered collection location, time since intervention, and calendar month. Analyses were completed using R version 4.4.1.

Research ethics approval

The trial was approved by the Kenya Medical Research Institute Scientific and Ethics Review Unit (KEMRI SERU: 4189), Institutional Review Board of the US Centers for Disease Control and Prevention (IRB: 00008118), and the Liverpool School of Tropical Medicine Research Ethics Committee (LSTM REC: 21-027). A license for the trial was also granted by the National Commission for Science, Technology, and Innovation (NACOSTI) in Kenya.

Role of the funding source

The ATSB study multi-country consortium, including researchers and technical advisors from IVCC (the funder), designed the trial and aligned it across the three countries [14, 15]. IVCC had no role in data collection, analysis, or interpretation, or writing of the report. All authors had full access to the study data and had final responsibility for the decision to submit for publication.

Results

Cohort recruitment

Of 4,509 children on the cohort recruitment lists (Fig1), 804 could not be contacted (399 intervention; 405 control), and 3,705 children were screened (1,858 control; 1,847 intervention). Of these, 523 children were not eligible (250 intervention; 273 control), and 220 did not consent (111 intervention; 109 control). Reasons for exclusion are detailed in Table S1. Overall, 2,962 children were enrolled (1,497 intervention; 1,465 control), including 1,000 in cohort-1, 969 in cohort-2, and 993 in cohort-3.

Characteristics of participants and households

Characteristics of cohort participants and households were similar in both arms (Table 1). The mean cluster-level proportion of children aged <5 years, 5-9 years, and 10-<15 years was 26.5% (SD 7.4%), 34.2% (SD 7.8%), and 39.3% (SD 8.9%), respectively. The median cluster-level prevalence of positive RDTs at enrolment was 45.7% (IQR: 28.6%, 67.9%) in the intervention arm and 48.7% (IQR: 24.3%, 61.8%) in the control. We surveyed 2,644 households of 2,886 (97%) participants. The cluster-level household size and socio-economic index were evenly distributed across both study arms. Most houses were classified as traditional construction, primarily due to open eaves. Nearly all households owned at least one bed net; however, the mean cluster-level proportion of households that owned at least one net for every two residents was only 51.4% (SD 9.7%).

286 **Table 1. Cluster-level characteristics of cohort participants & households (stratified by study arm)**

Variable	Characteristic	Cohort study	
		Control arm	Intervention arm
Number of clusters		35	35
Number of cohort participants enrolled		1,465	1,497
Female gender, mean (SD) [a]		47.1% (7.5%)	48.2% (7.2%)
Age categories, mean (SD) [a]	— 1 to < 5 years	27.5% (7.4%)	25.4% (7.4%)
	— 5 to 9 years	32.5% (7.1%)	35.9% (8.2%)
	— 10 to < 15 years	40.0% (8.0%)	38.6% (9.8%)
RDT positive, median (IQR) a		48.7% (24.3%, 61.8%)	45.7% (28.6%, 67.9%)
Number of households surveyed		1,311	1,333
Household size by cluster, mean (SD) [a]	— [1 - 4] residents	26.4% (7.3%)	24.7% (7.7%)
	— [5 - 7] residents	54.2% (9.0%)	56.1% (10.0%)
	— 8+ residents	17.8% (10.2%)	17.1% (9.5%)
Socioeconomic index in terciles, mean (SD) [a]	— Poorest	34.6% (10.7%)	31.3% (10.5%)
	— Poor	31.5% (8.3%)	34.3% (8.8%)
	— Least poor	33.9% (11.2%)	34.4% (11.2%)
Household construction, mean (SD) [a,b]	— Traditional	92.5% (5.0%)	92.2% (4.9%)
	— Modern	7.5% (5.0%)	7.8% (4.9%)
Net ownership, mean (SD) [a]	Households with at least one net	98.4% (2.4%)	98.8% (2.4%)
Adequate net coverage, mean (SD) [a]	Households with 1 net for every 2 residents	52.0% (9.7%)	50.8% (9.8%)

287 [a] *Proportions at the level of each cluster*

288 [b] *Houses were classified as 'modern' (synthetic walls and roofs, eaves closed or absent) or 'traditional' (all other construction)*

289

290 **ATSB delivery**

291 A total of 268,268 ATSBs were deployed between March 2022 and April 2024. Of the 33,419
292 household structures deemed eligible for ATSBs in March 2022, 183 did not consent, and another 56
293 did not receive ATSBs. Thus, 66,360 ATSBs were deployed to 33,180 (99.3%) structures. The mean
294 cluster-level coverage of ATSBs was 98.7% (range 96-100%) for eligible structures. In September
295 2022, March 2023, and September 2023, 66,868, 67,704, 67,336 ATSBs were deployed, respectively.
296 New structures were mapped and consented at each deployment round. Overall, during the 2-
297 monthly monitoring visits, 12,427 (4.6%) stations were missing (not present at the time of the
298 monitoring visit), and 42,297 (15.8%) met criteria for replacement, primarily due to mould, sugar
299 leakage, or damage, and were replaced with new ATSBs. All stations were replaced at the 6-month
300 mark. Further details on ATSB density and coverage will be published separately.

301

302 **Cohort follow-up**

303 Of the 2,962 children enrolled, 2,702 (91.2%) completed the 6th follow-up visit (1,375 intervention;
304 1,327 control). In cohort-3, 876 (88.2%) of 993 children completed the 12th follow-up visit (448
305 intervention; 428 control). Overall, 2,967 routine and sick visits (1,525 intervention; 1,442 control)
306 were associated with fever (elevated temperature $\geq$ 37.5^{o}C or history of fever in the past 48h). In the
307 intervention arm, 937 (71.5%) of 1,310 children tested with an RDT, and 131 (59.6%) of 220 children
308 tested by microscopy, were positive. In the control arm, 821 (66.4%) of 1,236 children tested with an
309 RDT, and 110 (49.8%) of 221 children tested by microscopy, were positive. Overall, 2,869 (96.9%)
310 participants (1,461 intervention, 1,408 control) were included in the primary endpoint analysis
311 (Fig1). Children were excluded if they missed the clearance visit, lacked a microscopy result at the
312 clearance visit (26 intervention; 37 control), or did not accrue eligible person-time after clearance (9
313 intervention; 18 control).

314

315 **Impact on primary outcome: clinical malaria incidence**

316 We captured 1,829 incident malaria cases over 1,445 person-years of follow-up. Malaria incidence
317 was 1.32 episodes per person-years in the intervention versus 1.20 in the control arm (Table 2).
318 There was no evidence of a difference in malaria incidence between the intervention and control
319 group in the unadjusted analysis (incidence rate ratio [IRR] 1.11; 95% CI: 0.75-1.65; p=0.598) or in
320 the multivariable analysis. The median cluster-level incidence of malaria overall was 1.275 cases per
321 person-year (range 0.04 to 4.59 cases per person-year). The coefficient of variation for malaria
322 incidence in the trial was 0.75. Subgroup analysis suggested that the effect of ATSBs varied by age (1-
323 <5 years: adjusted IRR 1.22 [95% CI: 0.84-1.77]; 5-<15 years: adjusted IRR 1.09 [95% CI: 0.77-1.53], p-
324 value for study arm x age group interaction=0.041) (Table 2). There were no sub-group differences
325 for other pre-specified factors. Overall, 18 serious adverse events (9 intervention; 9 control) were
326 reported; all were considered unrelated to the ATSB intervention (Table S2).
327
328

329 **Table 2. Malaria incidence (primary outcome)**

Study arm	Number of children	Episodes of malaria	Person years of observation at risk	Malaria Incidence	Unadjusted		Adjusted*	
					IRR (95% CI)	P value	IRR (95% CI)	P value
Overall								
Control	1408	857	711.64	1.20	Reference		Reference	
Intervention (ATSB)	1461	972	733.61	1.32	1.11 (0.75, 1.65)	0.598	1.10 (0.79, 1.52)	0.585
Age 1 to <5 years †								
Control	379	238	186.05	1.28	Reference		Reference	
Intervention (ATSB)	378	295	192.72	1.53	1.24 (0.76, 2.04)	0.565	1.22 (0.84, 1.77)	0.308
Age 5 to <15 years †								
Control	1029	619	525.59	1.18	Reference		Reference	
Intervention (ATSB)	1083	677	540.89	1.25	1.07 (0.74, 1.55)	0.728	1.09 (0.77, 1.53)	0.630

330 ** Adjusted for participant age, sex, adequate bednet coverage within household, housing, region, and baseline cluster-level malaria incidence (from baseline cohort)*

331 *† P-value = 0.041 for study arm x age category effect in primary outcome model fit with interaction term: ~ study arm + age category + study arm x age category, effect estimate for*
332 *interaction term 0.81 (0.66 - 0.99) (RR scale)*

333

334 **Impact on secondary outcomes: malaria prevalence**

335 In the cMIS survey, 7,488 community residents (3,760 intervention; 3,728 control) from 1,685
336 households (850 intervention; 835 control) were tested for malaria using RDTs (Table 3). Of these,
337 1,474 (39.2%) intervention and 1,461 (39.2%) control participants tested positive. There was no
338 difference in the odds of malaria infection between the two groups in the unadjusted analysis (odds
339 ratio [OR] 0.98; 95% CI: 0.60-1.59; p-value 0.93), or in the multivariable analysis (Table 3).

340

341

342 **Table 3. Secondary epidemiological and entomological outcomes**

Survey	Indicator	Study arm	Unadjusted			Adjusted	
			n/N (%)	OR (95% CI)	p-value	OR (95% CI)	p-value
Continuous malaria indicator survey	RDT positivity (all ages) *	Control	1461/3728 (39.19)	Ref		Ref	
		Intervention (ATSB)	1474/3760 (39.20)	0.98 (0.60–1.59)	0.93	0.97 (0.68–1.37)	0.85
Entomology surveillance	Parity (Female Anopheles spp.) †	Control	1973/2399 (82.2)	Ref		Ref	
		Intervention (ATSB)	3579/4058 (88.2)	1.34 (0.905–1.99)	0.14	1.30 (0.87–1.94)	0.201

Indicator	Study arm	Households sampled	Total Collected	Household Mean (SD)	Household Median (IQR)	Cluster Median (IQR)	IRR (95% CI)	p-value	IRR (95% CI)	p-value
Density by HLCs (Female *Anopheles spp.*)	Control	1925	10,846	5.63 (13.6)	0 (0 – 4)	2.06 (1.20–7.52)	Ref		Ref	
	Intervention	1924	28,840	15 (46)	0 (0 – 5)	0.913 (0.52–11.2)	0.954 (0.145–6.27)	0.96	0.985 (0.142–6.82)	0.99
Density by UVLTs (Female *Anopheles spp.*)	Control	1927	18,191	9.44 (22.1)	3 (0 – 9)	5.46 (3.93–10.8)	Ref		Ref	
	Intervention	1924	37,531	19.5 (52.7)	2 (0 – 14)	4.08 (1.96–22.5)	0.960 (0.257–3.59)	0.952	0.94 (0.244–3.63)	0.929
Density by UVLT CSS (Female *Anopheles spp.*)	Control	2103	22,797	10.8 (21.7)	3 (0 – 12)	7.15 (3.78–13.6)	Ref		Ref	
	Intervention	2104	29,792	14.2 (28.4)	3 (0 – 15)	5.58 (2.71–20.3)	1.02 (0.548–1.90)	0.952	0.954 (0.63–1.44)	0.822

343 ** cMIS analysis adjusted for study arm (ATSB), region, sex, age in year of survey & bednet use (slept under net last night)*

344 *† Parity analysis includes fixed effects for collection location (indoors vs. outdoors), time since intervention and calendar month as a seasonality adjustment*

345 *‡ Adjusted analysis for density includes fixed effects for study arm (ATSB) + log(baseline anopheline species number) and random effects for cluster & round*

346

347 **Impact on secondary outcomes: entomology indicators**

348 Between April 2022 and March 2024, 6,457 female *Anopheles spp* were collected and evaluated for
349 parity (4,058 intervention; 2,399 control) (Table 3). Of these, 3,579 (88.2%) in the intervention arm
350 and 1,973 (82.2%) in the control arm were parous. There was no difference in the odds of parity
351 between the groups in the unadjusted analysis (OR 1.34; 95% CI: 0.905-1.99; p=0.14), or in the
352 multivariable analysis. Similarly, no evidence of difference in the density of female *Anopheles spp*
353 was found when using human landing catches or UV light traps in the unadjusted or adjusted
354 analyses. Species-specific results for *An. funestus and An. gambiae* were similar, with no significant
355 differences in parity or density between the intervention and control groups stratified by species or
356 collection strategy (Table S3). Detailed results of the entomology surveys will be published
357 separately.

358

359 Discussion

360 In this trial, we evaluated the impact of ATSBs on malaria indicators in western Kenya. Despite
361 promising results from a preliminary entomology study in Mali [10], epidemiological modelling
362 suggesting that ATSBs could substantially reduce malaria burden in similar settings [11], and a choice
363 experiment in semi-field enclosures in Kenya suggesting that ATSBs were more attractive to local
364 *Anopheles* mosquitoes than natural sugar sources [12], we found no evidence that ATSBs reduced
365 malaria incidence in children aged 1-<15 years, malaria prevalence in community residents of all
366 ages, or vector parity or density in western Kenya. Our results are consistent with the findings from
367 the partner trial in Zambia, which found no impact of ATSBs on clinical malaria incidence, parasite
368 prevalence or entomological indicators in a setting with seasonal malaria transmission [24, 25]. The
369 lack of ATSB effectiveness is likely attributable to multiple factors, including competing sugar sources
370 for vector feeding in Kenya [26, 27], uncertainty about optimal intervention coverage in this setting,
371 product design and limited interaction with the product by local vector populations [10, 28]. For

ATSBs to effectively control malaria, a sufficient proportion of the mosquito population must be attracted to, subsequently feed on the insecticide-laced syrup in ATSB stations, and be killed, thus reducing the vector population and ultimately malaria transmission. It is unclear where along this pathway ATSBs failed in Kenya. However, the lack of entomological impact on vector density suggests that ATSBs did not work in western Kenya, as they appeared to in the Mali trial [10].

Why were ATSBs not effective in Kenya? Did ATSBs fail to lure mosquitoes, perhaps due to competition with other natural sugar sources? This seems plausible given the range and quantity of natural sugar sources in the environment which could lead to insufficient coverage [29]. Did mosquitoes fail to feed on the ATSBs, or did the insecticide fail to kill mosquitoes? This is possible, although laboratory experiments suggest that the mosquitoes did feed on the devices, and those that fed, died [30]. Or, was the proportion of mosquitoes affected by ATSBs insufficient to reduce vector density, parity and transmission in our setting? This seems most likely. Inadequate density and coverage of ATSB devices, the abundance of alternative food sources, or the sheer numbers of mosquitoes in the area may have all contributed. Modelling studies on mosquito feeding behaviour and the potential of ATSBs to control mosquito populations and *Plasmodium falciparum* malaria prevalence were fitted to data from Mali [11, 13]. However, natural sugar sources are more abundant in western Kenya than in Mali. The effectiveness of ATSBs may be context specific with higher efficacy in more arid regions. Studies in Mali and Israel, sites with less natural sugar sources, have demonstrated a strong entomological impact of ATSBs [10, 26, 31, 32]. However, in Zambia, the Phase III cluster-randomised trial evaluating ATSBs found that while vector density was reduced (but not significantly) by 35%, no difference was observed in parity, sporozoite rate or EIR [24], and correspondingly no significant reductions in clinical malaria incidence or malaria prevalence were observed [25]. Full results of the companion trial in Mali may shed more light on the efficacy of ATSBs in different settings.

398 Our study had several limitations. First, we currently lack a specific density target for spatial
399 deployment of ATSBs, and it remains unclear how bait stations interact with environmental factors
400 such as vector larval site locations, natural sugar sources, housing construction and human
401 settlement patterns. Further research is needed to better understand the impact of intervention
402 density and coverage, to optimise their effectiveness in diverse malaria transmission settings.
403 Second, the calculated coefficient of variation for malaria incidence, which measures heterogeneity
404 between clusters, was 0.75 in the trial, higher than the estimate of 0.4 included in our sample size
405 calculations. Underestimating coefficient of variation can compromise trial power and reduce effect
406 size precision in cluster-randomised trials [33]. However, all outcomes measured in this trial (malaria
407 incidence and prevalence, vector parity and density) were greater in the intervention arm than in
408 the control, suggesting that we were unlikely to have rejected the null hypothesis in the trial, even if
409 it had been more sufficiently powered to detect a statistically significant reduction in malaria
410 incidence.
411
412

413 # Conclusion

414 In a high transmission area in western Kenya, we found no evidence that ATSBs reduced malaria
415 incidence, prevalence, or vector parity and density, consistent with the results from the companion
416 trial in Zambia. Results from the partner trial Mali are expected soon, which may provide more
417 insight into the effectiveness of ATSBs in different transmission settings. Future work on ATSBs could
418 focus on steps in the causal pathway of impact (attraction, feeding, and mortality), the complex
419 interplay between sugar feeding and host seeking by malaria vectors, and density and coverage of
420 ATSBs in a variety of environmental and transmission settings. Further research on innovative
421 malaria control interventions is also needed to address outdoor biting and residual transmission, and
422 to help build the toolbox for integrated vector management.

Acknowledgments

We would like to thank the clinicians, monitors, community interviewers, human landing catch volunteers, the entomology laboratory and field teams, and community health promoters for their dedicated efforts in the collection of data and ensuring the smooth running of study activities. We are grateful to the social science team led by George Okello and Teresa Bange for helping us develop our community engagement strategy. We extend our appreciation to the Siaya County Ministry of Health for approving this study. We also thank the sub-county health management teams (Alego-Usonga and Rarieda) for facilitating community engagement and the health facility in-charges for their assistance with the cohort study and allowing their facilities to be used for storage of study supplies. Special thanks to Timothy Orwa the community liaison who was instrumental in community sensitization, Benta Kamire, Helen Wong, Sheila Nyarinda, and Maurice Ondeng for their instrumental roles in facilitating study activities, Dickens Riaga for ensuring the internal consistency of the trial and Dennis Omondi, the KEMRI/ CGHR Siaya laboratory manager for overseeing sample management. We are grateful to the Siaya County Commissioner and the national government staff who enabled us to conduct field activities without any issues. Lastly, we are grateful to all participants for their willingness to take part in this trial.

Author's contributions

EO, FtK, and AMS conceived the trial, with input from DM, JJ, MJD, and SK. EO, FtK, and AMS designed the study, developed the procedures, and drafted the protocol with contributions from DM, ML, JJ, CO, MC, MM, OT, WO, KO1, BS, SO, JK, and BP. CO, KO1, BS, SO, JK, and BP led field activities and data collection, under the oversight of SGS, FtK, AMS, and EO, with support from JS, JRG, JEG, and MJD. AK, DM, FA, and OT managed the data, and ML led the data analysis, with support from AK, DM and SGS. SO and JK led the entomology surveillance

and mosquito sample processing. KO2 coordinated the collection, processing, and storage of blood samples. CO and SGS interpreted the data and drafted the manuscript, with input from ML, DM, and AK. All authors reviewed the manuscript and approved it for publication. CO, the corresponding author, had full access to all the data in the study and held final responsibility for the decision to submit the manuscript for publication.

Declaration of interests

The authors declare that they have no competing interests.

Funding statement

This work was funded by Integrated Vector Control Consortium (IVCC), UK, through support from the Bill & Melinda Gates Foundation (grant: INV-007509), the Swiss Agency for Development and Cooperation (SDC) (grant: 81067480) and UK Aid (grant: 30041-105). The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation, SDC or UK Aid.

Data sharing statement

De-identified data are available from the corresponding author on reasonable request. Following publication of forthcoming secondary analyses of trial data, the de-identified trial dataset will be posted on a public repository.

468 # Figure legends

469 **Fig1: CONSORT flow diagram**

470

471 **Fig2: Map of study area:** The study included 70 clusters, each consisting of a minimum of 100
472 households in the core area. Clusters were randomised 1:1 to intervention (ATSB) or control
473 (standard care). A sub-set of 16 clusters were randomly selected for entomology surveillance.

474

475 **Fig3: Study schema**. Timeline of study activities between February 2022 to March 2024
476 Abbreviations – attractive targeted sugar bait (ATSB), continuous malaria indicator survey (cMIS),
477 human landing catches (HLCs), ultraviolet light traps (UVLTs), cross-sectional surveys (CSS). Activities
478 featured, include: four rounds of ATSB deployment and monitoring; enrolment and follow-up of
479 three consecutive cohorts of children; two years of cMIS monitoring; seven cross-sectional mosquito
480 collections using UVLTs; one year of entomology surveillance using HLCs and UVLTs for mosquito
481 collections.

482

483 # Supplemental files

484 **S1. Malaria microscopy procedures**

485 **Table S1. Cohort study recruitment**

486 **Table S2. Serious adverse events & deaths**

487 **Table S3. Additional parity outcomes**

References

1. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015;526(7572):207-11. doi: 10.1038/nature15535. PubMed PMID: 26375008.

2. World Health Organization. World Malaria Report 2023. Geneva, Switzerland: World Health Organization, 2023.

3. Ranson H, Lissenden N. Insecticide Resistance in African Anopheles Mosquitoes: A Worsening Situation that Needs Urgent Action to Maintain Malaria Control. Trends Parasitol. 2016;32(3):187-96. doi: 10.1016/j.pt.2015.11.010. PubMed PMID: 26826784.

4. Abong'o B, Gimnig JE, Torr SJ, Longman B, Omoke D, Muchoki M, et al. Impact of indoor residual spraying with pirimiphos-methyl (Actellic 300CS) on entomological indicators of transmission and malaria case burden in Migori County, western Kenya. Scientific reports. 2020;10(1):4518. Epub 20200311. doi: 10.1038/s41598-020-61350-2. PubMed PMID: 32161302; PubMed Central PMCID: PMCPMC7066154.

5. Omondi S, Kosgei J, Musula G, Muchoki M, Abong'o B, Agumba S, et al. Late morning biting behaviour of Anopheles funestus is a risk factor for transmission in schools in Siaya, western Kenya. Malar J. 2023;22(1):366. Epub 2023/12/01. doi: 10.1186/s12936-023-04806-w. PubMed PMID: 38037026; PubMed Central PMCID: PMCPMC10691009.

6. Conrad MD, Asua V, Garg S, Giesbrecht D, Niaré K, Smith S, et al. Evolution of Partial Resistance to Artemisinins in Malaria Parasites in Uganda. N Engl J Med. 2023;389(8):722-32. Epub 2023/08/23. doi: 10.1056/NEJMoa2211803. PubMed PMID: 37611122; PubMed Central PMCID: PMCPMC10513755.

7. Alegana VA, Macharia PM, Muchiri S, Mumo E, Oyugi E, Kamau A, et al. Plasmodium falciparum parasite prevalence in East Africa: Updating data for malaria stratification. PLOS Glob Public Health. 2021;1(12):e0000014. Epub 2022/02/26. doi: 10.1371/journal.pgph.0000014. PubMed PMID: 35211700; PubMed Central PMCID: PMCPMC7612417.

8. Odero JI, Abong'o B, Moshi V, Ekodir S, Harvey SA, Ochomo E, et al. Early morning anopheline mosquito biting, a potential driver of malaria transmission in Busia County, western Kenya. Malar J. 2024;23(1):66. Epub 20240304. doi: 10.1186/s12936-024-04893-3. PubMed PMID: 38438933; PubMed Central PMCID: PMCPMC10910777.

9. Njoroge TM, Hamid-Adiamoh M, Duman-Scheel M. Maximizing the Potential of Attractive Targeted Sugar Baits (ATSBs) for Integrated Vector Management. Insects. 2023;14(7). Epub 20230628. doi: 10.3390/insects14070585. PubMed PMID: 37504591; PubMed Central PMCID: PMCPMC10380652.

10. Traore MM, Junnila A, Traore SF, Doumbia S, Revay EE, Kravchenko VD, et al. Large-scale field trial of attractive toxic sugar baits (ATSB) for the control of malaria vector mosquitoes in Mali,

West Africa. Malar J. 2020;19(1):72. Epub 20200214. doi: 10.1186/s12936-020-3132-0. PubMed PMID: 32059671; PubMed Central PMCID: PMCPMC7023716.

11. Fraser KJ, Mwandigha L, Traore SF, Traore MM, Doumbia S, Junnila A, et al. Estimating the potential impact of Attractive Targeted Sugar Baits (ATSBs) as a new vector control tool for Plasmodium falciparum malaria. Malar J. 2021;20(1):151. Epub 20210317. doi: 10.1186/s12936-021-03684-4. PubMed PMID: 33731111; PubMed Central PMCID: PMCPMC7968277.

12. Chanda J, Wagman J, Chanda B, Kaniki T, Ng'andu M, Muyabe R, et al. Feeding rates of malaria vectors from a prototype attractive sugar bait station in Western Province, Zambia: results of an entomological validation study. Malar J. 2023;22(1):70. Epub 20230301. doi: 10.1186/s12936-023-04491-9. PubMed PMID: 36855105; PubMed Central PMCID: PMCPMC9974387.

13. Marshall JM, White MT, Ghani AC, Schlein Y, Muller GC, Beier JC. Quantifying the mosquito's sweet tooth: modelling the effectiveness of attractive toxic sugar baits (ATSB) for malaria vector control. Malar J. 2013;12:291. Epub 20130823. doi: 10.1186/1475-2875-12-291. PubMed PMID: 23968494; PubMed Central PMCID: PMCPMC3765557.

14. Attractive Targeted Sugar Bait Phase III Trial Group. Attractive targeted sugar bait phase III trials in Kenya, Mali, and Zambia. Trials. 2022;23(1):640. Epub 2022/08/10. doi: 10.1186/s13063-022-06555-8. PubMed PMID: 35945599; PubMed Central PMCID: PMCPMC9361277.

15. Yukich J, Eisele TP, terKuile F, Ashton R, Staedke S, Harris AF, et al. Master statistical analysis plan: attractive targeted sugar bait phase III trials in Kenya, Mali, and Zambia. Trials. 2023;24(1):771. Epub 2023/11/30. doi: 10.1186/s13063-023-07762-7. PubMed PMID: 38031086; PubMed Central PMCID: PMCPMC10685482.

16. Kamau A, Obiet K, Ogwang C, McDermott DP, Lesosky M, Janssen J, et al. Attractive targeted sugar baits for malaria control in western Kenya (ATSB-Kenya): enrolment characteristics of cohort children and households. Malar J. 2024;23(1):403. Epub 20241230. doi: 10.1186/s12936-024-05234-0. PubMed PMID: 39736740; PubMed Central PMCID: PMCPMC11687092.

17. Odhiambo FO, Laserson KF, Sewe M, Hamel MJ, Feikin DR, Adazu K, et al. Profile: the KEMRI/CDC Health and Demographic Surveillance System--Western Kenya. Int J Epidemiol. 2012;41(4):977-87. doi: 10.1093/ije/dys108. PubMed PMID: 22933646.

18. Odero NA, Samuels AM, Odongo W, Abong'o B, Gimnig J, Otieno K, et al. Community-based intermittent mass testing and treatment for malaria in an area of high transmission intensity, western Kenya: development of study site infrastructure and lessons learned. Malar J. 2019;18(1):255. Epub 20190729. doi: 10.1186/s12936-019-2896-6. PubMed PMID: 31357997; PubMed Central PMCID: PMCPMC6664589.

19. Samuels AM, Odero NA, Odongo W, Otieno K, Were V, Shi YP, et al. Impact of Community-Based Mass Testing and Treatment on Malaria Infection Prevalence in a High-Transmission Area of Western Kenya: A Cluster Randomized Controlled Trial. Clin Infect Dis. 2021;72(11):1927-35. doi: 10.1093/cid/ciaa471. PubMed PMID: 32324850; PubMed Central PMCID: PMCPMC9059430.

561 20. Bayoh MN, Mathias DK, Odiere MR, Mutuku FM, Kamau L, Gimnig JE, et al. Anopheles gambiae:
562 historical population decline associated with regional distribution of insecticide-treated bed nets
563 in western Nyanza Province, Kenya. Malaria journal. 2010;9:62. Epub 2010/03/02. doi:
564 10.1186/1475-2875-9-62. PubMed PMID: 20187956; PubMed Central PMCID: PMC2838909.

565 21. US President's Malaria Initiative. U.S. President's Malaria Initiative Kenya Malaria Operational
566 Plan, FY 2023. 2022.

567 22. Detinova TS. Age-grouping methods in Diptera of medical importance with special reference to
568 some vectors of malaria. Monogr Ser World Health Organ. 1962;47:13-191. PubMed PMID:
569 13885800.

570 23. Johnson PC, Barry SJ, Ferguson HM, Müller P. Power analysis for generalized linear mixed models
571 in ecology and evolution. Methods Ecol Evol. 2015;6(2):133-42. Epub 20141206. doi:
572 10.1111/2041-210x.12306. PubMed PMID: 25893088; PubMed Central PMCID:
573 PMCPMC4394709.

574 24. Wagman J, Chanda B, Chanda J, Saili K, Orange E, Mambo P, et al. Entomological effects of
575 attractive targeted sugar bait station deployment in Western Zambia: vector surveillance
576 findings from a two-arm cluster randomized phase III trial. Malar J. 2024;23(1):214. Epub
577 20240718. doi: 10.1186/s12936-024-05045-3. PubMed PMID: 39026236; PubMed Central
578 PMCID: PMCPMC11264679.

579 25. Ashton RA, Saili K, Chishya C, Banda Yikona H, Arnzen A, Orange E, et al. Efficacy of attractive
580 targeted sugar bait stations against malaria in Western Province Zambia: epidemiological
581 findings from a two-arm cluster randomized phase III trial. Malar J. 2024;23(1):343. Epub
582 20241115. doi: 10.1186/s12936-024-05175-8. PubMed PMID: 39548456; PubMed Central
583 PMCID: PMCPMC11566550.

584 26. Beier JC, Muller GC, Gu W, Arheart KL, Schlein Y. Attractive toxic sugar bait (ATSB) methods
585 decimate populations of Anopheles malaria vectors in arid environments regardless of the local
586 availability of favoured sugar-source blossoms. Malar J. 2012;11:31. Epub 20120201. doi:
587 10.1186/1475-2875-11-31. PubMed PMID: 22297155; PubMed Central PMCID:
588 PMCPMC3293779.

589 27. Yalla N, Polo B, McDermott DP, Kosgei J, Omondi S, Agumba S, et al. A comparison of the
590 attractiveness of flowering plant blossoms versus attractive targeted sugar baits (ATSBs) in
591 western Kenya. PLoS One. 2023;18(6):e0286679. Epub 20230606. doi:
592 10.1371/journal.pone.0286679. PubMed PMID: 37279239; PubMed Central PMCID:
593 PMCPMC10243617.

594 28. Diarra RA, Traore MM, Junnila A, Traore SF, Doumbia S, Revay EE, et al. Testing configurations of
595 attractive toxic sugar bait (ATSB) stations in Mali, West Africa, for improving the control of
596 malaria parasite transmission by vector mosquitoes and minimizing their effect on non-target
597 insects. Malar J. 2021;20(1):184. Epub 20210414. doi: 10.1186/s12936-021-03704-3. PubMed
598 PMID: 33853632; PubMed Central PMCID: PMCPMC8048058.

29. Omondi S, Kosgei J, Agumba S, Polo B, Yalla N, Moshi V, et al. Natural sugar feeding rates of Anopheles mosquitoes collected by different methods in western Kenya. Scientific reports. 2022;12(1):20596. Epub 20221129. doi: 10.1038/s41598-022-25004-9. PubMed PMID: 36446923; PubMed Central PMCID: PMCPMC9709062.

30. Mwaanga G, Ford J, Yukich J, Chanda B, Ashton RA, Chanda J, et al. Residual bioefficacy of attractive targeted sugar bait stations targeting malaria vectors during seasonal deployment in Western Province of Zambia. Malaria Journal. 2024;23(1):169. doi: 10.1186/s12936-024-04990-3.

31. Müller GC, Beier JC, Traore SF, Toure MB, Traore MM, Bah S, et al. Successful field trial of attractive toxic sugar bait (ATSB) plant-spraying methods against malaria vectors in the Anopheles gambiae complex in Mali, West Africa. Malaria Journal. 2010;9(1):210. doi: 10.1186/1475-2875-9-210.

32. Revay EE, Schlein Y, Tsabari O, Kravchenko V, Qualls W, De-Xue R, et al. Formulation of attractive toxic sugar bait (ATSB) with safe EPA-exempt substance significantly diminishes the Anopheles sergentii population in a desert oasis. Acta Trop. 2015;150:29-34. Epub 20150625. doi: 10.1016/j.actatropica.2015.06.018. PubMed PMID: 26119042; PubMed Central PMCID: PMCPMC4720916.

33. Biggs J, Challenger JD, Hellewell J, Churcher TS, Cook J. A systematic review of sample size estimation accuracy on power in malaria cluster randomised trials measuring epidemiological outcomes. medRxiv. 2024:2024.04.08.24305485. doi: 10.1101/2024.04.08.24305485.


70 clusters randomised
32 in Alego Usonga
38 in Rarieda
35 clusters randomised to control
35 clusters randomised to intervention
Cohort 1 recruitment
887 on recruitment list
223 failed to contact
664 screened
Cohort 2 recruitment
665 recruitment list
77 failed to contact
588 screened
Cohort 3 recruitment
700 recruitment list
105 failed to contact
595 screened
Cohort 1 recruitment
892 on recruitment list
217 failed to contact
675 screened
Cohort 2 recruitment
665 recruitment list
84 failed to contact
581 screened
Cohort 3 recruitment
700 recruitment list
98 failed to contact
602 screened
Cohort 1 screening
168 excluded
115 not eligible
53 declined
Cohort 2 screening
103 excluded
71 not eligible
32 declined
Cohort 3 screening
111 excluded
87 not eligible
24 declined
Cohort 1 screening
171 excluded
118 not eligible
53 declined †
Cohort 2 screening
97 excluded
59 not eligible
38 declined †
Cohort 3 screening
93 excluded
73 not eligible
20 declined †
Cohort 1 enrolment
496 enrolled
Cohort 2 enrolment
485 enrolled
Cohort 3 enrolment
484 enrolled
Cohort 1 enrolment
504 enrolled
Cohort 2 enrolment
484 enrolled
Cohort 3 enrolment
509 enrolled
Cohort 1 follow-up
34 endpoint exclusions
23 clearance failure*
11 no person-time
after clearance
Cohort 2 follow-up
13 endpoint exclusions
10 clearance failure*
3 no person-time
after clearance
Cohort 3 follow-up
10 endpoint exclusions
6 clearance failure*
4 no person-time
after clearance
Cohort 1 follow-up
19 endpoint exclusions
16 clearance failure*
3 no person-time
after clearance
Cohort 2 follow-up
10 endpoint exclusions
8 clearance failure*
2 no person-time
after clearance
Cohort 3 follow-up
7 endpoint exclusions
3 clearance failure*
4 no person-time
after clearance
Cohort 1 analysis
462 in endpoint analysis
Cohort 2 analysis
472 in endpoint analysis
Cohort 3 analysis
474 in endpoint analysis
Cohort 1 analysis
485 in endpoint analysis
Cohort 2 analysis
474 in endpoint analysis
Cohort 3 analysis
502 in endpoint analysis

Figure


N
Kenya
Ugenya
Ugunja
Alego Usonga
Gem
Bondo
Rarieda
Study sub counties
Intervention clusters
Control clusters
Entomology clusters
Lakes
Study Health Facilities
0
5
10 km

Figure


Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sept
Oct
Nov
Dec
2022
ATSB Round 1 deployment
ATSB Round 1 monitoring
ATSB Round 2 deployment
ATSB Round 2 monitoring
Cohort 1 recruitment
Cohort 1 follow-up
Cohort 2 recruitment
Cohort 2 follow-up
Continuous Malaria Indicator Survey (cMIS) Year 1
Human landing catches (HLCs) & UV light traps (UVLTs) Year 1
UVLT CSS
UVLT CSS
UVLT CSS
2023
ATSB Round 2
ATSB Round 3 deployment
ATSB Round 3 monitoring
ATSB Round 4 deployment
ATSB Round 4 monitoring
Cohort 2 follow-up
Cohort 3 recruitment
Cohort 3 follow-up
cMIS Year 1
cMIS Year 2
HLCs & UVLTs
HLCs & UVLTs Year 2
UVLT CSS
UVLT CSS
UVLT CSS
2024
ATSB Round 4
Cohort 3 follow-up
cMIS Year 2
HLCs & UVLTs
UVLT CSS

Figure